Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier

摘要

An anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like is described. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.

主权项

1. A nucleic acid encoding a heavy chain variable region or a light chain variable region of an anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibody capable of specifically binding to an extracellular domain of human CCR7,
the antibody being produced by a hybridoma FERM BP-11369, FERM BP-11404, FERM BP-11371, FERM BP-11372, FERM BP-11373, FERM BP-11374, FERM BP-11375, or FERM BP-11376, and wherein the antibody is capable of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation, without relying on complement-dependent cell lysis action or antibody-dependent cell-mediated cytotoxicity.